



661 Sunnybrook Road
Suite 100
Ridgeland, MS 39157

601.326.1000
888.821.0202

HORNE.COM

March 21, 2022

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
Canadian Securities Exchange

Dear Sirs / Madames:

Re: GeneTether, Inc.

We refer to the prospectus of GeneTether Therapeutics Inc. (the "Company") dated March 21, 2022 relating to the initial public offering of units of the Company.

We consent to being named and to the use in the above-mentioned prospectus, of our reports dated October 25, 2021 to the shareholders and Board of Directors of GeneTether, Inc. on the following financial statements:

- Statements of financial position as at December 31, 2020, 2019 and 2018;
- Statements of loss and comprehensive loss, changes in shareholders' equity (deficiency) and cash flows for the years ended December 31, 2020 and 2019 and the period from inception (February 12, 2018) to December 31, 2018, and a summary of significant accounting policies and other explanatory information.

We report that we have read the prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

A handwritten signature in black ink that reads 'HORNE LLP' in a cursive, slightly stylized font.

HORNE LLP
Ridgeland, Mississippi